1
|
Rivoal M, Dubuquoy L, Millet R, Leleu-Chavain N. Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target. J Med Chem 2023; 66:14391-14410. [PMID: 37857324 DOI: 10.1021/acs.jmedchem.3c00593] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]
Abstract
Receptor interacting serine/threonine protein kinase 2 (RIPK2) is a downstream signaling molecule essential for the activation of several innate immune receptors, including the NOD-like receptors (NOD1 and NOD2). Recognition of pathogen-associated molecular pattern proteins by NOD1/2 leads to their interaction with RIPK2, which induces release of pro-inflammatory cytokines through the activation of NF-κB and MAPK pathways, among others. Thus, RIPK2 has emerged as a key mediator of intracellular signal transduction and represents a new potential therapeutic target for the treatment of various conditions, including inflammatory diseases and cancer. In this Perspective, first, an overview of the mechanisms that underlie RIPK2 function will be presented along with its role in several diseases. Then, the existing inhibitors that target RIPK2 and different therapeutic strategies will be reviewed, followed by a discussion on current challenges and outlook.
Collapse
Affiliation(s)
- Morgane Rivoal
- Inserm, U1286 - INFINITE - Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille, France
| | - Laurent Dubuquoy
- Inserm, U1286 - INFINITE - Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille, France
| | - Régis Millet
- Inserm, U1286 - INFINITE - Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille, France
| | - Natascha Leleu-Chavain
- Inserm, U1286 - INFINITE - Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille, France
| |
Collapse
|
2
|
Zhao W, Leng RX, Ye DQ. RIPK2 as a promising druggable target for autoimmune diseases. Int Immunopharmacol 2023; 118:110128. [PMID: 37023697 DOI: 10.1016/j.intimp.2023.110128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 03/21/2023] [Accepted: 03/29/2023] [Indexed: 04/07/2023]
Abstract
Receptor Interacting Serine/Threonine Kinase 2 (RIPK2) is an essential regulator of the inflammatory process and immune response. In innate immunity, the NOD-RIPK2 signaling axis is an important pathway that directly mediates inflammation and immune response. In adaptive immunity, RIPK2 may affect T cell proliferation, differentiation and cellular homeostasis thereby involving T cell-driven autoimmunity, but the exact mechanism remains unclear. Recent advances suggest a key role of RIPK2 in diverse autoimmune diseases (ADs) such as inflammatory bowel diseases, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and Behcet's disease. This review aims to provide valuable therapeutic direction for ADs by focusing on the function and modulation of RIPK2 in innate and adaptive immunity, its involvement with various ADs and the application of RIPK2-related drugs in ADs. We raise the notion that drug targeting RIPK2 could be a promising therapeutic strategy for the treatment of ADs, though much work remains to be done for clinical application.
Collapse
|
3
|
Pham AT, Ghilardi AF, Sun L. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases. Front Pharmacol 2023; 14:1127722. [PMID: 36959850 PMCID: PMC10028200 DOI: 10.3389/fphar.2023.1127722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 02/21/2023] [Indexed: 03/09/2023] Open
Abstract
Receptor-interacting serine/threonine kinase 2 (RIPK2) is a vital immunomodulator that plays critical roles in nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs) signaling. Stimulated NOD1 and NOD2 interact with RIPK2 and lead to the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPK), followed by the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12/23. Defects in NOD/RIPK2 signaling are associated with numerous inflammatory diseases, including asthma, sarcoidosis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), multiple sclerosis, and Blau syndrome. As RIPK2 is a crucial element of innate immunity, small molecules regulating RIPK2 functions are attractive to establish novel immunotherapies. The increased interest in developing RIPK2 inhibitors has led to the clinical investigations of novel drug candidates. In this review, we attempt to summarize recent advances in the development of RIPK2 inhibitors and degraders.
Collapse
|
4
|
Ermann J, Matmusaev M, Haley EK, Braun C, Jost F, Mayer-Wrangowski S, Hsiao P, Ting N, Li L, Terenzio D, Chime J, Lukas S, Patnaude L, Panzenbeck M, Csordas D, Zheng J, Mierz D, Simpson T, King FJ, Klimowicz AP, Mbow ML, Fine JS, Miller CA, Fogal SE, Byrne FR. The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2021; 321:G500-G512. [PMID: 34494462 DOI: 10.1152/ajpgi.00163.2021] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Accepted: 08/30/2021] [Indexed: 01/31/2023]
Abstract
Mouse and human data implicate the NOD1 and NOD2 sensors of the intestinal microbiome and the associated signal transduction via the receptor interacting protein kinase 2 (RIPK2) as a potential key signaling node for the development of inflammatory bowel disease (IBD) and an attractive target for pharmacological intervention. The TRUC mouse model of IBD was strongly indicated for evaluating RIPK2 antagonism for its effect on intestinal inflammation based on previous knockout studies with NOD1, NOD2, and RIPK2. We identified and profiled the BI 706039 molecule as a potent and specific functional inhibitor of both human and mouse RIPK2 and with favorable pharmacokinetic properties. We dosed BI 706039 in the spontaneous TRUC mouse model from age 28 to 56 days. Oral, daily administration of BI 706039 caused dose-responsive and significant improvement in colonic histopathological inflammation, colon weight, and terminal levels of protein-normalized fecal lipocalin (all P values <0.001). These observations correlated with dose responsively increasing systemic levels of the BI 706039 compound, splenic molecular target engagement of RIPK2, and modulation of inflammatory genes in the colon. This demonstrates that a relatively low oral dose of a potent and selective RIPK2 inhibitor can modulate signaling in the intestinal immune system and significantly improve disease associated intestinal inflammation.NEW & NOTEWORTHY The RIPK2 kinase at the apex of microbiome immunosensing is an attractive target for pharmacological intervention. A low oral dose of a RIPK2 inhibitor leads to significantly improved intestinal inflammation in the murine TRUC model of colitis. A selective and potent inhibitor of the RIPK2 kinase may represent a new class of therapeutics that target microbiome-driven signaling for the treatment of IBD.
Collapse
Affiliation(s)
- Joerg Ermann
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Mederbek Matmusaev
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts
| | - Emma K Haley
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts
| | - Clemens Braun
- Department of Drug Discovery Sciences, Boehringer-Ingelheim Pharmaceuticals Incorporated, Biberach, Germany
| | - Felix Jost
- Department of Drug Discovery Sciences, Boehringer-Ingelheim Pharmaceuticals Incorporated, Biberach, Germany
| | - Svenja Mayer-Wrangowski
- Department of Drug Discovery Sciences, Boehringer-Ingelheim Pharmaceuticals Incorporated, Biberach, Germany
| | - Peng Hsiao
- Department of Drug Discovery Sciences, Boehringer-Ingelheim Pharmaceuticals Incorporated, Biberach, Germany
| | - Naitee Ting
- Department of Global Computational Biology and Data Sciences, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Li Li
- Department of Global Computational Biology and Data Sciences, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Donna Terenzio
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Jane Chime
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Susan Lukas
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Lori Patnaude
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Mark Panzenbeck
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - David Csordas
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Jie Zheng
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Diane Mierz
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Tom Simpson
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - F James King
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Alex P Klimowicz
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - M Lamine Mbow
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Jay S Fine
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Craig A Miller
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Steve E Fogal
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| | - Fergus R Byrne
- Department of Immunology and Respiratory Diseases Research, Boehringer-Ingelheim Pharmaceuticals Incorporated, Ridgefield, Connecticut
| |
Collapse
|
5
|
Han Y, Wang J, Li S, Li Y, Zhang Y, Zhang R, Zhang Y, Fan H, Shi H, Pan J, Song G, Ge L, Wang L. Isopsoralen ameliorates rheumatoid arthritis by targeting MIF. Arthritis Res Ther 2021; 23:243. [PMID: 34535196 PMCID: PMC8447788 DOI: 10.1186/s13075-021-02619-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 08/27/2021] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Isopsoralen (IPRN), one of the active ingredients of Psoralea corylifolia Linn, has anti-inflammatory properties. We attempted to investigate the inhibitory effects of IPRN on rheumatoid arthritis (RA) and characterize its potential mechanism. METHODS RA fibroblast-like synoviocytes (FLSs) and mice with collagen-induced arthritis (CIA) were used as in vitro and in vivo models to analyze the antiarthritic effect of IPRN. Histological analysis of the inflamed joints from mice with CIA was performed using microcomputed tomography (micro-CT) and hematoxylin-eosin (HE) staining. RNA sequencing (RNA-Seq), network pharmacology analysis, molecular docking, drug affinity responsive target stability (DARTS) assay, and cellular thermal shift assay (CETSA) were performed to evaluate the targets of IPRN. RESULTS IPRN ameliorated the inflammatory phenotype of RA FLSs by inhibiting their cytokine production, migration, invasion, and proangiogenic ability. IPRN also significantly reduced the severity of CIA in mice by decreasing paw thickness, arthritis score, bone damage, and serum inflammatory cytokine levels. A mechanistic study demonstrated that macrophage migration inhibitory factor (MIF), a key protein in the inflammatory process, was the specific target by which IPRN exerted its anti-inflammatory effects in RA FLSs. CONCLUSION Our study demonstrates the antiarthritic effect of IPRN, which suggests the therapeutic potential of IPRN in RA.
Collapse
Affiliation(s)
- Yi Han
- China Academy of Chinese Medical Sciences, Guang'anmen Hospital, Beijing, China
| | - Jinguang Wang
- Department of Orthopedics, Dezhou People's Hospital, Dezhou, Shandong, China
| | - Shufeng Li
- Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, China
| | - Yi Li
- Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Yongli Zhang
- Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
| | - Ruojia Zhang
- Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
| | - Yuang Zhang
- Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China
- Biomedical Sciences College & Shandong Medicinal Biotechnology Center, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, #18877, Jingshi Road, Jinan, 250062, China
| | - Huancai Fan
- Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
| | - Haojun Shi
- The Second Clinical Medical College, Henan University of Chinese Medicine, Jinan, China
| | - Jihong Pan
- Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China
- Biomedical Sciences College & Shandong Medicinal Biotechnology Center, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, #18877, Jingshi Road, Jinan, 250062, China
| | - Guanhua Song
- Institute of Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
| | - Luna Ge
- Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
- Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
- Biomedical Sciences College & Shandong Medicinal Biotechnology Center, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, #18877, Jingshi Road, Jinan, 250062, China.
| | - Lin Wang
- Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
- Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
- Biomedical Sciences College & Shandong Medicinal Biotechnology Center, Key lab for Biotech-Drugs of National Health Commission, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, #18877, Jingshi Road, Jinan, 250062, China.
| |
Collapse
|
6
|
Topal Y, Gyrd-Hansen M. RIPK2 NODs to XIAP and IBD. Semin Cell Dev Biol 2021; 109:144-150. [DOI: 10.1016/j.semcdb.2020.07.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 06/30/2020] [Accepted: 07/01/2020] [Indexed: 12/22/2022]
|
7
|
Miller MH, Shehat MG, Tigno-Aranjuez JT. Immune Modulation of Allergic Asthma by Early Pharmacological Inhibition of RIP2. Immunohorizons 2020; 4:825-836. [PMID: 33443037 DOI: 10.4049/immunohorizons.2000073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Accepted: 12/01/2020] [Indexed: 11/19/2022] Open
Abstract
Exposure to house dust mite (HDM) is highly associated with the development of allergic asthma. The adaptive immune response to HDM is largely Th2 and Th17 dominant, and a number of innate immune receptors have been identified that recognize HDM to initiate these responses. Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is a cytosolic sensor of peptidoglycan, which is important for Th2 and Th17 polarization. NOD2 mediates its signaling through its downstream effector kinase, receptor-interacting serine/threonine protein kinase 2 (RIP2). We have previously shown that RIP2 promotes HDM-associated allergic airway inflammation and Th2 and Th17 immunity, acting early in the HDM response and likely within airway epithelial cells. However, the consequences of inhibiting RIP2 during this critical period has not yet been examined. In this study, we pharmacologically inhibited RIP2 activity during the initial exposure to allergen in an acute HDM model of asthma and determined the effect on the subsequent development of allergic airway disease. We show that early inhibition of RIP2 was sufficient to reduce lung histopathology and local airway inflammation while reducing the Th2 immune response. Using a chronic HDM asthma model, we demonstrate that inhibition of RIP2, despite attenuating airway inflammation and airway remodeling, was insufficient to reduce airway hyperresponsiveness. These data demonstrate the potential of pharmacological targeting of this kinase in asthma and support further development and optimization of RIP2-targeted therapies.
Collapse
Affiliation(s)
- Madelyn H Miller
- Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827
| | - Michael G Shehat
- Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827
| | - Justine T Tigno-Aranjuez
- Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827
| |
Collapse
|
8
|
Li Y, Lin P, Wang S, Li S, Wang R, Yang L, Wang H. Quantitative analysis of differentially expressed proteins in psoriasis vulgaris using tandem mass tags and parallel reaction monitoring. Clin Proteomics 2020; 17:30. [PMID: 32817748 PMCID: PMC7425065 DOI: 10.1186/s12014-020-09293-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 08/06/2020] [Indexed: 12/29/2022] Open
Abstract
Background Psoriasis vulgaris (PV) is a chronic autoimmune inflammatory disease with epidermal hyperkeratosis and parakeratosis. Methods The study was to elucidate the pathogenesis of PV by quantitative proteomic analysis of skin lesion biopsies of PV and healthy tissues with tandem mass tags (TMTs) coupled with liquid chromatography–mass spectrometry (LC–MS)/MS. Results A total of 4562 differentially expressed proteins (DEPs) between PV lesional tissues (n = 11) and healthy tissues (n = 11) were identified, of which 299 were upregulated and 206 were downregulated using |fold change| > 1.3 as the cutoff threshold. The Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis revealed that the DEPs were mainly enriched in the activation of immune cells (drug metabolism pathway, NOD-like pathway, and IL-17 pathway), cell proliferation (ribosomal pathway, DNA replication pathway, and base replication pathway), metabolism-related pathways (fatty acid biosynthesis and metabolism, PPAR pathway, glycerophospholipid metabolism, and cortisol synthesis and breakdown), and glandular secretion (saliva secretion, gastric acid secretion, and pancreatic fluid secretion). Thirteen DEPs that were relatively highly expressed in the drug metabolism pathway were validated with parallel reaction monitoring (PRM), of which MPO, TYMP, IMPDH2, GSTM4, and ALDH3A1 were highly expressed in PV, whereas CES1, MAOB, MGST1, and GSTT1 were less expressed in PV. Conclusions These findings confirmed that these proteins participate in the drug metabolism-other enzyme pathways and play crucial roles in the activation and proliferation of immune cells in the pathogenesis of PV.
Collapse
Affiliation(s)
- Yu Li
- Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China
| | - Peng Lin
- Shenzhen Luohu District Hospital of Traditional Chinese Medicine, Shenzhen, Guangdong People's Republic of China
| | - Siyao Wang
- Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China
| | - Shuang Li
- Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China
| | - Rui Wang
- Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China
| | - Lin Yang
- Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, People's Republic of China
| | - Hongmei Wang
- Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, People's Republic of China
| |
Collapse
|
9
|
Jensen S, Seidelin JB, LaCasse EC, Nielsen OH. SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Sci Signal 2020; 13:13/619/eaax8295. [PMID: 32071170 DOI: 10.1126/scisignal.aax8295] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
New therapeutic approaches for chronic inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis are needed because current treatments are often suboptimal in terms of both efficacy and the risks of serious adverse events. Inhibitor of apoptosis proteins (IAPs) are E3 ubiquitin ligases that inhibit cell death pathways and are themselves inhibited by second mitochondria-derived activator of caspases (SMAC). SMAC mimetics (SMs), small-molecule antagonists of IAPs, are being evaluated as cancer therapies in clinical trials. IAPs are also crucial regulators of inflammatory pathways because they influence both the activation of inflammatory genes and the induction of cell death through the receptor-interacting serine-threonine protein kinases (RIPKs), nuclear factor κB (NF-κB)-inducing kinase, and mitogen-activated protein kinases (MAPKs). Furthermore, there is an increasing interest in specifically targeting the substrates of IAP-mediated ubiquitylation, especially RIPK1, RIPK2, and RIPK3, as druggable nodes in inflammation control. Several studies have revealed an anti-inflammatory potential of RIPK inhibitors that either block inflammatory signaling or block the form of inflammatory cell death known as necroptosis. Expanding research on innate immune signaling through pattern recognition receptors that stimulate proinflammatory NF-κB and MAPK signaling may further contribute to uncovering the complex molecular roles used by IAPs and downstream RIPKs in inflammatory signaling. This may benefit and guide the development of SMs or selective RIPK inhibitors as anti-inflammatory therapeutics for various chronic inflammatory conditions.
Collapse
Affiliation(s)
- Simone Jensen
- Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, 1 Borgmester Ib Juuls Vej, DK-2730 Herlev, Denmark
| | - Jakob Benedict Seidelin
- Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, 1 Borgmester Ib Juuls Vej, DK-2730 Herlev, Denmark.
| | - Eric Charles LaCasse
- Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, Ontario K1H 8L1, Canada
| | - Ole Haagen Nielsen
- Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, 1 Borgmester Ib Juuls Vej, DK-2730 Herlev, Denmark
| |
Collapse
|
10
|
Hwang HS, Lee MH, Choi MH, Kim HA. NOD2 signaling pathway is involved in fibronectin fragment-induced pro-catabolic factor expressions in human articular chondrocytes. BMB Rep 2020. [PMID: 30760380 PMCID: PMC6605519 DOI: 10.5483/bmbrep.2019.52.6.165] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The nucleotide-binding and oligomerization domain (NOD) is an innate pattern recognition receptor that recognizes pathogen- and damage-associated molecular patterns. The 29-kDa amino-terminal fibronectin fragment (29-kDa FN-f) is a matrix degradation product found in the synovial fluids of patients with osteoarthritis (OA). We investigated whether NOD2 was involved in 29-kDa FN-f-induced pro-catabolic gene expression in human chondrocytes. The expression of mRNA and protein was measured using quantitative real-time polymerase chain reaction (qrt-PCR) and Western blot analysis. Small interfering RNAs were used for knockdown of NOD2 and toll-like receptor 2 (TLR-2). An immunoprecipitation assay was performed to examine protein interactions. The NOD2 levels in human OA cartilage were much higher than in normal cartilage. NOD1 and NOD2 expression, as well as pro-inflammatory cytokines, including interleukin-1beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), were upregulated by 29-kDa FN-f in human chondrocytes. NOD2 silencing showed that NOD2 was involved in the 29-kDa FN-f-induced expression of TLR-2. Expressions of IL-6, IL-8, matrix metalloproteinase (MMP)-1, -3, and -13 were also suppressed by TLR-2 knockdown. Furthermore, NOD2 and TLR-2 knockdown data demonstrated that both NOD2 and TLR-2 modulated the expressions of their adaptors, receptor-interacting protein 2 (RIP2) and myeloid differentiation 88, in 29-kDa FN-f-treated chondrocytes. 29-kDa FN-f enhanced the interaction of NOD2, RIP2 and transforming growth factor beta-activated kinase 1 (TAK1), an indispensable signaling intermediate in the TLR-2 signaling pathway, and activated nuclear factor-κB (NF-κB), subsequently leading to increased expressions of pro-inflammatory cytokines and cartilage-degrading enzymes. These results demonstrate that 29-kDa FN-f modulated pro-catabolic responses via cross-regulation of NOD2 and TLR-2 signaling pathways.
Collapse
Affiliation(s)
- Hyun Sook Hwang
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| | - Mi Hyun Lee
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| | - Min Ha Choi
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| | - Hyun Ah Kim
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| |
Collapse
|
11
|
Abstract
The cGAS-STING pathway plays an important role in pathogen-induced activation of the innate immune response. The 29-kDa amino-terminal fibronectin fragment (29-kDa FN-f) found predominantly in the synovial fluid of osteoarthritis (OA) patients increases the expression of catabolic factors via the toll-like receptor-2 (TLR-2) signaling pathway. In this study, we investigated whether 29-kDa FN-f induces inflammatory responses via the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon gene (STING) pathway in human primary chondrocytes. The levels of cGAS and STING were elevated in OA cartilage compared with normal cartilage. Long-term treatment of chondrocytes with 29-kDa FN-f activated the cGAS/STING pathway together with the increased level of gamma-H2AX, a marker of DNA breaks. In addition, the expression of pro-inflammatory cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF/CSF-2), granulocyte colony-stimulating factor (G-CSF/CSF-3), and type I interferon (IFN-α), was increased more than 100-fold in 29-kDa FN-f-treated chondrocytes. However, knockdown of cGAS and STING suppressed 29-kDa FN-f-induced expression of GM-CSF, G-CSF, and IFN-α together with the decreased activation of TANK-binding kinase 1 (TBK1), interferon regulatory factor 3 (IRF3), and inhibitor protein κBα (IκBα). Furthermore, NOD2 or TLR-2 knockdown suppressed the expression of GM-CSF, G-CSF, and IFN-α as well as decreased the activation of the cGAS/STING pathway in 29-kDa FN-f-treated chondrocytes. These data demonstrate that the cGAS/STING/TBK1/IRF3 pathway plays a critical role in 29-kDa FN-f-induced expression of pro-inflammatory cytokines.
Collapse
Affiliation(s)
- Hyun Sook Hwang
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| | - Mi Hyun Lee
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| | - Min Ha Choi
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| | - Hyun Ah Kim
- Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang 14068; Institute for Skeletal Aging, Hallym University, Chunchon 24251, Korea
| |
Collapse
|
12
|
Shehat MG, Cardona OA, Aranjuez GF, Jewett MW, Tigno-Aranjuez JT. RIP2 promotes FcγR-mediated reactive oxygen species production. J Biol Chem 2019; 294:10365-10378. [PMID: 31113864 DOI: 10.1074/jbc.ra118.007218] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 05/02/2019] [Indexed: 11/06/2022] Open
Abstract
Receptor-interacting protein 2 (RIP2) is a kinase that mediates signaling downstream of the bacterial peptidoglycan sensors NOD1 and NOD2. Genetic loss or pharmaceutical inhibition of RIP2 has been shown to be beneficial in multiple inflammatory disease models with the effects largely attributed to reducing proinflammatory signaling downstream of peptidoglycan recognition. However, given the widespread expression of this kinase and its reported interactions with numerous other proteins, it is possible that RIP2 may also function in roles outside of peptidoglycan sensing. In this work, we show that RIP2 undergoes tyrosine phosphorylation and activation in response to engagement of the Fc γ receptor (FcγR). Using bone marrow-derived macrophages from WT and RIP2-KO mice, we show that loss of RIP2 leads to deficient FcγR signaling and reactive oxygen species (ROS) production upon FcγR cross-linking without affecting cytokine secretion, phagocytosis, or nitrate/nitrite production. The FcγR-induced ROS response was still dependent on NOD2, as macrophages deficient in this receptor showed similar defects. Mechanistically, we found that different members of the Src family kinases (SFKs) can promote RIP2 tyrosine phosphorylation and activation. Altogether, our findings suggest that RIP2 is functionally important in pathways outside of bacterial peptidoglycan sensing and that involvement in such pathways may depend on the actions of SFKs. These findings will have important implications for future therapies designed to target this kinase.
Collapse
Affiliation(s)
- Michael G Shehat
- From the Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827
| | - Omar A Cardona
- From the Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827
| | - George F Aranjuez
- From the Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827
| | - Mollie W Jewett
- From the Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827
| | - Justine T Tigno-Aranjuez
- From the Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827
| |
Collapse
|
13
|
Napimoga MH, Clemente-Napimoga JT, Machabanski NM, Juliani MEA, Acras PHBC, Macedo CG, Abdalla HB, de Pinho AJ, Soares AB, Sperandio M, de Araújo DR. The 15d‑PGJ2 hydrogel ameliorates atopic dermatitis through suppression of the immune response. Mol Med Rep 2019; 19:4536-4544. [PMID: 31059034 PMCID: PMC6522822 DOI: 10.3892/mmr.2019.10156] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 01/15/2019] [Indexed: 01/30/2023] Open
Abstract
The present study examined the efficacy of the topical 15d-PGJ2-poloxamer 407 hydrogel in an atopic dermatitis (AD) animal model. The 15d-PGJ2 hydrogel was prepared and characterized. The examined rats possessed AD-Like cutaneous lesions, which were induced using 2,4-dinitrochlorobenzene, the rats were then treated with a hydrogel vehicle, 15d-PGJ2 hydrogel or tacrolimus for 14 days. The rats were sacrificed and blood samples were collected to quantify the IgE levels. Subsequently, skin biopsies were stained with toluidine blue to identify mast cells and immunohistochemistry was performed for ROR-γt and TNF-α. Histological analyses demonstrated that 15d-PGJ2 hydrogel significantly decreased mast cell infiltration (P<0.05) when compared with the AD-group. Tacrolimus at 0.1% exhibited decreased mast cell infiltration; however, this difference was not statistically significant from the AD-group. Topical 15d-PGJ2 hydrogel and Tacrolimus 0.1% significantly reduced the serum levels of IgE (P<0.05) compared with the AD-group. Immunohistochemistry revealed a significant decrease in ROR-γt and TNF-α positive cell expression (P<0.05) in the 15d-PGJ2 hydrogel group compared with the AD-group. In summary, topical administration of 15d-PGJ2 hydrogel had a beneficial effect on AD symptoms, suggesting that this formulation may be a useful strategy for the treatment of AD.
Collapse
Affiliation(s)
- Marcelo H Napimoga
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Juliana T Clemente-Napimoga
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Nina M Machabanski
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Maria Eduarda A Juliani
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Pedro Henrique B C Acras
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Cristina G Macedo
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Henrique B Abdalla
- Laboratory of Orofacial Pain, Department of Physiology, Piracicaba Dental School, State University of Campinas, Piracicaba, São Paulo 13414‑903, Brazil
| | - Antônio José de Pinho
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Andresa B Soares
- Department of Oral Pathology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Marcelo Sperandio
- Department of Oral Pathology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045‑755, Brazil
| | - Daniele R de Araújo
- Center of Human and Natural Sciences, Federal University of ABC, Santo André, São Paulo 09210‑580, Brazil
| |
Collapse
|
14
|
Spiller F, Oliveira Formiga R, Fernandes da Silva Coimbra J, Alves-Filho JC, Cunha TM, Cunha FQ. Targeting nitric oxide as a key modulator of sepsis, arthritis and pain. Nitric Oxide 2019; 89:32-40. [PMID: 31051258 DOI: 10.1016/j.niox.2019.04.011] [Citation(s) in RCA: 76] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 03/22/2019] [Accepted: 04/29/2019] [Indexed: 12/25/2022]
Abstract
Nitric oxide (NO) is produced by enzymatic activity of neuronal (nNOS), endothelial (eNOS), and inducible nitric oxide synthase (iNOS) and modulates a broad spectrum of physiological and pathophysiological conditions. The iNOS isoform is positively regulated at transcriptional level and produces high levels of NO in response to inflammatory mediators and/or to pattern recognition receptor signaling, such as Toll-like receptors. In this review, we compiled the main contributions of our group for understanding of the role of NO in sepsis and arthritis outcome and the peripheral contributions of NO to inflammatory pain development. Although neutrophil iNOS-derived NO is necessary for bacterial killing, systemic production of high levels of NO impairs neutrophil migration to infections through inhibiting neutrophil adhesion on microcirculation and their locomotion. Moreover, neutrophil-derived NO contributes to multiple organ dysfunction in sepsis. In arthritis, NO is chief for bacterial clearance in staphylococcal-induced arthritis; however, it contributes to articular damage and bone mass degradation. NO produced in inflammatory sites also downmodulates pain. The mechanism involved in analgesic effect and inhibition of neutrophil migration is dependent on the activation of the classical sGC/cGMP/PKG pathway. Despite the increasing number of studies performed after the identification of NO as an endothelium-derived relaxing factor, the underlying mechanisms of NO in inflammatory diseases remain unclear.
Collapse
Affiliation(s)
- Fernando Spiller
- Department of Pharmacology, Federal University of Santa Catarina (UFSC), Florianopolis, Brazil.
| | | | | | | | - Thiago Mattar Cunha
- Department of Pharmacology, Ribeiro Preto Medical School, University of Sao Paulo, Brazil
| | - Fernando Queiroz Cunha
- Department of Pharmacology, Ribeiro Preto Medical School, University of Sao Paulo, Brazil.
| |
Collapse
|
15
|
A Network Pharmacology Study on the Active Ingredients and Potential Targets of Tripterygium wilfordii Hook for Treatment of Rheumatoid Arthritis. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2019; 2019:5276865. [PMID: 31118961 PMCID: PMC6500618 DOI: 10.1155/2019/5276865] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 02/23/2019] [Accepted: 02/28/2019] [Indexed: 12/11/2022]
Abstract
Traditional Chinese medicine has specific effect on some chronic diseases in clinic, especially in rheumatic diseases. Tripterygium wilfordii Hook (TWH) is a traditional Chinese medicine commonly used in the treatment of rheumatoid arthritis (RA); the unique therapeutic effect has been confirmed by a large number of research papers. TWH has many compounds that lead to its active compounds. However, the potential targets and pharmacological and molecular mechanism of its action treatment of rheumatic diseases are not entirely clear. Therefore, the network pharmacology approach is needed to further study and explore its treatment mechanism. We have successfully set up 10 networks, including four major networks and other networks. Four major networks include rheumatoid arthritis disease network, compound-compound target network of TWH, TWH compound target-rheumatoid arthritis disease network, and TWH-rheumatoid arthritis disease-mechanism network. Other networks consist of RA disease and TWH related targets clusters, biological processes, and pathways network. Our study successfully predicted, explained, and confirmed the TWH of RA disease molecular synergy and found the potential of RA related targets, cluster, biological process, and pathways. This study not only provides prompts to the researcher who explores pharmacological and biological molecular mechanism of TWH applying to RA disease, but also proves a feasible method for discovering potential activated compounds from Chinese herbs.
Collapse
|
16
|
Jurynec MJ, Sawitzke AD, Beals TC, Redd MJ, Stevens J, Otterud B, Leppert MF, Grunwald DJ. A hyperactivating proinflammatory RIPK2 allele associated with early-onset osteoarthritis. Hum Mol Genet 2019; 27:2383-2391. [PMID: 29659823 DOI: 10.1093/hmg/ddy132] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 04/09/2018] [Indexed: 12/13/2022] Open
Abstract
Osteoarthritis (OA) is a common debilitating disease characterized by abnormal remodeling of the cartilage and bone of the articular joint. Ameliorating therapeutics are lacking due to limited understanding of the molecular pathways affecting disease initiation and progression. Notably, although a link between inflammation and overt OA is well established, the role of inflammation as a driver of disease occurrence is highly disputed. We analyzed a family with dominant inheritance of early-onset OA and found that affected individuals harbored a rare variant allele encoding a significant amino acid change (p.Asn104Asp) in the kinase domain of receptor interacting protein kinase 2 (RIPK2), which transduces signals from activated bacterial peptidoglycan sensors through the NF-κB pathway to generate a proinflammatory immune response. Functional analyses of RIPK2 activity in zebrafish embryos indicated that the variant RIPK2104Asp protein is hyperactive in its signaling capacity, with augmented ability to activate the innate immune response and the NF-κB pathway and to promote upregulation of OA-associated genes. Further we show a second allele of RIPK2 linked to an inflammatory disease associated with arthritis also has enhanced activity stimulating the NF-κB pathway. Our studies reveal for the first time the inflammatory response can function as a gatekeeper risk factor for OA.
Collapse
Affiliation(s)
- Michael J Jurynec
- Department of Orthopaedics, University of Utah, Salt Lake City, 84112, USA
| | - Allen D Sawitzke
- Division of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, 84112, USA
| | - Timothy C Beals
- Department of Orthopaedics, University of Utah, Salt Lake City, 84112, USA
| | - Michael J Redd
- Health Sciences Center Imaging Core Facility, Salt Lake City, 84112, USA
| | - Jeff Stevens
- Department of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA
| | - Brith Otterud
- Department of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA
| | - Mark F Leppert
- Department of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA
| | | |
Collapse
|
17
|
Naringenin mitigates titanium dioxide (TiO 2)-induced chronic arthritis in mice: role of oxidative stress, cytokines, and NFκB. Inflamm Res 2018; 67:997-1012. [PMID: 30370484 DOI: 10.1007/s00011-018-1195-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 09/14/2018] [Accepted: 10/12/2018] [Indexed: 10/28/2022] Open
Abstract
OBJECTIVE To evaluate the effect and mechanisms of naringenin in TiO2-induced chronic arthritis in mice, a model resembling prosthesis and implant inflammation. TREATMENT Flavonoids are antioxidant and anti-inflammatory molecules with important anti-inflammatory effect. Mice were daily treated with the flavonoid naringenin (16.7-150 mg/kg, orally) for 30 days starting 24 h after intra-articular knee injection of 3 mg of TiO2. METHODS TiO2-induced arthritis resembles cases of aseptic inflammation induced by prosthesis and/or implants. Mice were stimulated with 3 mg of TiO2 and after 24 h mice started to be treated with naringenin. The disease phenotype, treatment toxicity, histopathological damage, oxidative stress, cytokine expression and NFκB were evaluated after 30 days of treatment. RESULTS Naringenin inhibited TiO2-induced mechanical hyperalgesia (96%), edema (77%) and leukocyte recruitment (74%) without inducing toxicity. Naringenin inhibited histopathological index (HE, 49%), cartilage damage (Toluidine blue tibial staining 49%, and proteoglycan 98%), and bone resorption (TRAP-stained 73%). These effects were accompanied by inhibition of oxidative stress (gp91phox 93%, NBT 83%, and TBARS 41%) cytokine mRNA expression (IL-33 82%, TNFα 76%, pro-IL-1β 100%, and IL-6 61%), and NFκB activation (100%). CONCLUSION Naringenin ameliorates TiO2-induced chronic arthritis inducing analgesic and anti-inflammatory responses with improvement in the histopathological index, cartilage damage, and bone resorption.
Collapse
|
18
|
Vanaki N, Golmohammadi T, Jamshidi A, Akhtari M, Vojdanian M, Mostafaei S, Poursani S, Ahmadzadeh N, Mahmoudi M. Increased inflammatory responsiveness of peripheral blood mononuclear cells (PBMCs) to in vitro NOD2 ligand stimulation in patients with ankylosing spondylitis. Immunopharmacol Immunotoxicol 2018; 40:393-400. [PMID: 30265175 DOI: 10.1080/08923973.2018.1510963] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Background: Ankylosing spondylitis (AS) is a common debilitating rheumatic disease in which the innate immune components especially the Interleukin (IL)-23/IL-17 axis related genes play important role in its pathogenesis. Nucleotide binding oligomerization domain-containing protein (NOD)2, as an innate receptor, is critical for IL-23 production in cells. Therefore, we aimed to stimulate NOD2 signaling and study its effects on cytokine production in peripheral blood mononuclear cells (PBMC) of these patients. Methods: PBMCs from 18 patients with active AS and 18 healthy individuals were separated by Ficoll-Hypaque density gradient centrifugation and cultured in the presence of muramyl dipeptide (MDP), as NOD2 ligand. Quantitative expression analysis of NOD1, NOD2, RIPK2, SLC15A4, NLRP1, NLRP3, IL23A, IL17A, IL1B, and TNFA genes was performed using Real-time polymerase chain reaction (PCR). Finally, protein changes of IL23A and IL17A expression were validated using enzyme linked immunosorbent assay (ELISA). Results: Apart from NOD1 that tend to be downregulated in the controls, all the selected genes showed overexpression in response to MDP in cells from the studied groups. Except RIPK2, all the genes had higher expression changes upon MDP stimulation in the AS population. Overexpression of IL23A and IL17A were confirmed at protein levels using ELISA. The strong positive correlation between NLRP3 and NOD2 was decreased after stimulation but new correlations between NLRP3 and IL1B, RIPK2 and SLC15A4 were observed after treatment. Conclusions: This study indicated that AS PBMCs were hyper-responsive to MDP stimulation. This observation implies an important role of NOD2 in the pathogenesis of inflammatory diseases including AS.
Collapse
Affiliation(s)
- Negar Vanaki
- a Department of Biochemistry, Faculty of Medicine , Tehran University of Medical Sciences , Tehran , Iran.,b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran
| | - Taghi Golmohammadi
- a Department of Biochemistry, Faculty of Medicine , Tehran University of Medical Sciences , Tehran , Iran
| | - Ahmadreza Jamshidi
- b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran
| | - Maryam Akhtari
- b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran.,c Department of Cell and Molecular Biology , School of Biology, College of Science, University of Tehran , Tehran , Iran
| | - Mahdi Vojdanian
- b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran
| | - Shayan Mostafaei
- b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran
| | - Shiva Poursani
- b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran
| | - Nooshin Ahmadzadeh
- b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran
| | - Mahdi Mahmoudi
- b Rheumatology Research Center, Tehran University of Medical Sciences , Tehran , Iran
| |
Collapse
|
19
|
Napier RJ, Lee EJ, Vance EE, Snow PE, Samson KA, Dawson CE, Moran AE, Stenzel P, Davey MP, Sakaguchi S, Rosenzweig HL. Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis. THE JOURNAL OF IMMUNOLOGY 2018; 201:1889-1898. [PMID: 30150283 DOI: 10.4049/jimmunol.1700507] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Accepted: 07/27/2018] [Indexed: 12/11/2022]
Abstract
Arthritis in a genetically susceptible SKG strain of mice models a theoretical paradigm wherein autoimmune arthritis arises because of interplay between preexisting autoreactive T cells and environmental stimuli. SKG mice have a point mutation in ZAP-70 that results in attenuated TCR signaling, altered thymic selection, and spontaneous production of autoreactive T cells that cause arthritis following exposure to microbial β-glucans. In this study, we identify Nod2, an innate immune receptor, as a critical suppressor of arthritis in SKG mice. SKG mice deficient in Nod2 (Nod2-/-SKG) developed a dramatically exacerbated form of arthritis, which was independent of sex and microbiota, but required the skg mutation in T cells. Worsened arthritis in Nod2-/-SKG mice was accompanied by expansion of Th17 cells, which to some measure coproduced TNF, GM-CSF, and IL-22, along with elevated IL-17A levels within joint synovial fluid. Importantly, neutralization of IL-17A mitigated arthritis in Nod2-/-SKG mice, indicating that Nod2-mediated protection occurs through suppression of the Th17 response. Nod2 deficiency did not alter regulatory T cell development or function. Instead, Nod2 deficiency resulted in an enhanced fundamental ability of SKG CD4+ T cells (from naive mice) to produce increased levels of IL-17 and to passively transfer arthritis to lymphopenic recipients on a single-cell level. These data reveal a previously unconsidered role for T cell-intrinsic Nod2 as an endogenous negative regulator of Th17 responses and arthritogenic T cells. Based on our findings, future studies aimed at understanding a negative regulatory function of Nod2 within autoreactive T cells could provide novel therapeutic strategies for treatment of patients with arthritis.
Collapse
Affiliation(s)
- Ruth J Napier
- Veterans Affairs Portland Health Care System, Portland, OR 97239.,Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239
| | - Ellen J Lee
- Veterans Affairs Portland Health Care System, Portland, OR 97239.,Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239
| | - Emily E Vance
- Veterans Affairs Portland Health Care System, Portland, OR 97239.,Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239
| | - Paige E Snow
- Veterans Affairs Portland Health Care System, Portland, OR 97239
| | - Kimberly A Samson
- Veterans Affairs Portland Health Care System, Portland, OR 97239.,Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239
| | - Clare E Dawson
- Veterans Affairs Portland Health Care System, Portland, OR 97239
| | - Amy E Moran
- Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97239
| | - Peter Stenzel
- Department of Anatomic Pathology, Oregon Health & Science University, Portland, OR 97239
| | - Michael P Davey
- Veterans Affairs Portland Health Care System, Portland, OR 97239.,Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239.,Department of Medicine, Oregon Health & Science University, Portland, OR 97239; and
| | | | - Holly L Rosenzweig
- Veterans Affairs Portland Health Care System, Portland, OR 97239; .,Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239
| |
Collapse
|
20
|
Salla M, Aguayo-Ortiz R, Danmaliki GI, Zare A, Said A, Moore J, Pandya V, Manaloor R, Fong S, Blankstein AR, Gibson SB, Garcia LR, Meier P, Bhullar KS, Hubbard BP, Fiteh Y, Vliagoftis H, Goping IS, Brocks D, Hwang P, Velázquez-Martínez CA, Baksh S. Identification and Characterization of Novel Receptor-Interacting Serine/Threonine-Protein Kinase 2 Inhibitors Using Structural Similarity Analysis. J Pharmacol Exp Ther 2018; 365:354-367. [PMID: 29555876 DOI: 10.1124/jpet.117.247163] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 02/26/2018] [Indexed: 12/16/2022] Open
Abstract
Receptor-interacting protein kinase 2 (RIP2 or RICK, herein referred to as RIPK2) is linked to the pathogen pathway that activates nuclear factor κ-light-chain-enhancer of activated B cells (NFκB) and autophagic activation. Using molecular modeling (docking) and chemoinformatics analyses, we used the RIPK2/ponatinib crystal structure and searched in chemical databases for small molecules exerting binding interactions similar to those exerted by ponatinib. The identified RIPK2 inhibitors potently inhibited the proliferation of cancer cells by > 70% and also inhibited NFκB activity. More importantly, in vivo inhibition of intestinal and lung inflammation rodent models suggests effectiveness to resolve inflammation with low toxicity to the animals. Thus, our identified RIPK2 inhibitor may offer possible therapeutic control of inflammation in diseases such as inflammatory bowel disease, asthma, cystic fibrosis, primary sclerosing cholangitis, and pancreatitis.
Collapse
Affiliation(s)
- Mohamed Salla
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Rodrigo Aguayo-Ortiz
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Gaddafi I Danmaliki
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Alaa Zare
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Ahmed Said
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Jack Moore
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Vrajeshkumar Pandya
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Robin Manaloor
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Sunny Fong
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Anna R Blankstein
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Spencer B Gibson
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Laura Ramos Garcia
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Pascal Meier
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Khushwant S Bhullar
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Basil P Hubbard
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Yahya Fiteh
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Harissios Vliagoftis
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Ing Swie Goping
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Dion Brocks
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Peter Hwang
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Carlos A Velázquez-Martínez
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Shairaz Baksh
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| |
Collapse
|
21
|
Stafford CA, Lawlor KE, Heim VJ, Bankovacki A, Bernardini JP, Silke J, Nachbur U. IAPs Regulate Distinct Innate Immune Pathways to Co-ordinate the Response to Bacterial Peptidoglycans. Cell Rep 2018; 22:1496-1508. [DOI: 10.1016/j.celrep.2018.01.024] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 11/02/2017] [Accepted: 01/08/2018] [Indexed: 12/19/2022] Open
|
22
|
Wang X, Bai J, Jia Z, Zhu Y, Liu J, Zhang K, Hao D, Heng L. A time-course microarray data analysis reveals consistent dysregulated genes and upstream microRNAs in autoantibody-mediated arthritis. J Orthop Surg Res 2017; 12:186. [PMID: 29197380 PMCID: PMC5712098 DOI: 10.1186/s13018-017-0674-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Accepted: 11/03/2017] [Indexed: 12/17/2022] Open
Abstract
Background The purpose of this study is to identify key genes and microRNAs (miRNAs) involved in autoantibody-mediated arthritis (AMA). Methods A time-course microarray data (ID: GSE27492) of peripheral blood leukocytes, ankle tissue, and synovial fluid from K/BxN mouse serum-transferred mice were downloaded from Gene Expression Omnibus. Those samples were collected at days 0, 1, 3, 7, 12, and 18 after serum injection. Limma of R was employed to identify differentially expressed genes (DEGs) in samples collected at days 1–18 compared with those collected at day 0. Consistent DEGs were obtained by taking the interaction of DEGs from different time points, followed by functional enrichment analysis. MiRNAs were screened out and constructed into regulatory network with DEGs using Cytoscape. Results In total, 17 consistent DEGs were obtained, including downregulated Ephx1 and upregulated AF251705, Adam8, Arg1, Basp1, Ccl2, Ccl7, Ccl9, Ccr2, Clec4a2, Clec4d, Cxcl1, Fabp5, Fcgr1, Gp49a, Il1rn, and Saa3. Those DEGs were associated with biological processes of immune response, inflammatory response, and defense response; chemokine signaling pathway; cytokine-cytokine receptor interaction; and NOD-like receptor signaling pathway. Additionally, 202 miRNAs were identified to have a regulatory effect on 9 of the 17 DEGs. Notably, miR-944, miR-374a, and miR374b were found to regulate the expression of Cxcl1, Ccl7, and Ccl2. Clec4d was targeted by 78 miRNAs. Conclusions Our study reveals that 17 DEGs and 202 miRNAs may be associated with autoimmune disorder in the progression of AMA, which could guide future researches.
Collapse
Affiliation(s)
- Xinwen Wang
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, 555 East Youyi Road, Xi'an, 710054, Shaanxi, People's Republic of China
| | - Jie Bai
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, 555 East Youyi Road, Xi'an, 710054, Shaanxi, People's Republic of China
| | - Zhen Jia
- Department of Endocrinology, Xi'an No. 1 Hospital, Xi'an, 710002, Shaanxi, People's Republic of China
| | - Yangjun Zhu
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, 555 East Youyi Road, Xi'an, 710054, Shaanxi, People's Republic of China
| | - Jijun Liu
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, 555 East Youyi Road, Xi'an, 710054, Shaanxi, People's Republic of China
| | - Kun Zhang
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, 555 East Youyi Road, Xi'an, 710054, Shaanxi, People's Republic of China
| | - Dingjun Hao
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, 555 East Youyi Road, Xi'an, 710054, Shaanxi, People's Republic of China
| | - Lisong Heng
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, 555 East Youyi Road, Xi'an, 710054, Shaanxi, People's Republic of China.
| |
Collapse
|
23
|
Borghi SM, Mizokami SS, Pinho-Ribeiro FA, Fattori V, Crespigio J, Clemente-Napimoga JT, Napimoga MH, Pitol DL, Issa JPM, Fukada SY, Casagrande R, Verri WA. The flavonoid quercetin inhibits titanium dioxide (TiO 2)-induced chronic arthritis in mice. J Nutr Biochem 2017; 53:81-95. [PMID: 29197723 DOI: 10.1016/j.jnutbio.2017.10.010] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 05/31/2017] [Accepted: 10/16/2017] [Indexed: 01/14/2023]
Abstract
Titanium dioxide (TiO2) is a common component of orthopedic prosthesis. However, prosthesis wear releases TiO2, which induces inflammation and osteolysis in peri-prosthetic tissues. Quercetin is a flavonoid widely present in human diet, which presents biological activities such as antinociceptive, anti-inflammatory and antioxidant effects. Therefore, the effect of intraperitoneal treatment with quercetin in TiO2-induced arthritis model was evaluated. In the first set of experiments, mice received injection of TiO2 (0.1-3 mg/knee joint) and articular mechanical hyperalgesia, edema and histopathology analysis were performed in a 30 days protocol. The dose of 3 mg of TiO2 showed the most harmful effect, and was chosen to the following experiments. Subsequently, mice received 3 mg of TiO2 followed by post-treatment with quercetin during 30 days. Quercetin (10-100 mg/kg) inhibited in a dose-dependent manner TiO2-induced knee joint mechanical hyperalgesia, edema and leukocyte recruitment and did not induce damage in major organs such as liver, kidney and stomach. The dose of 30 mg/kg was chosen for the subsequent analysis, and reduced histopathological changes such as leukocyte infiltration, vascular proliferation and synovial hyperplasia (pannus formation) on day 30 after TiO2 challenge. The protective analgesic and anti-inflammatory mechanisms of quercetin included the inhibition of TiO2-induced neutrophil and macrophage recruitment, proteoglycan degradation, oxidative stress, cytokine production (TNF-α, IL-1β, IL-6, and IL-10), COX-2 mRNA expression, and bone resorption as well as activation of Nrf2/HO-1 signaling pathway. These results demonstrate the potential therapeutic applicability of the dietary flavonoid quercetin to reduce pain and inflammatory damages associated with prosthesis wear process-induced arthritis.
Collapse
Affiliation(s)
- Sergio M Borghi
- Department of Pathology, Center of Biological Sciences, State University of Londrina, 86057-970, Londrina, Paraná, Brazil
| | - Sandra S Mizokami
- Department of Pathology, Center of Biological Sciences, State University of Londrina, 86057-970, Londrina, Paraná, Brazil
| | - Felipe A Pinho-Ribeiro
- Department of Pathology, Center of Biological Sciences, State University of Londrina, 86057-970, Londrina, Paraná, Brazil
| | - Victor Fattori
- Department of Pathology, Center of Biological Sciences, State University of Londrina, 86057-970, Londrina, Paraná, Brazil
| | - Jefferson Crespigio
- Department of Pathology, Center of Biological Sciences, State University of Londrina, 86057-970, Londrina, Paraná, Brazil
| | - Juliana T Clemente-Napimoga
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, 13045-755, Campinas, São Paulo, Brazil
| | - Marcelo H Napimoga
- Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, 13045-755, Campinas, São Paulo, Brazil
| | - Dimitrius L Pitol
- Department of Morphology, Physiology and Basic Pathology, School of Dentistry, University of São Paulo, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - João P M Issa
- Department of Morphology, Physiology and Basic Pathology, School of Dentistry, University of São Paulo, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Sandra Y Fukada
- Department of Physics and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Rubia Casagrande
- Department of Pharmaceutical Sciences, University Hospital (Health Science Centre), Londrina State University, 86038-350, Londrina, Paraná, Brazil
| | - Waldiceu A Verri
- Department of Pathology, Center of Biological Sciences, State University of Londrina, 86057-970, Londrina, Paraná, Brazil.
| |
Collapse
|
24
|
Staurengo-Ferrari L, Ruiz-Miyazawa KW, Pinho-Ribeiro FA, Domiciano TP, Fattori V, Mizokami SS, Pelayo JS, Bordignon J, Figueiredo F, Casagrande R, Miranda KM, Verri WA. The nitroxyl donor Angeli's salt ameliorates Staphylococcus aureus-induced septic arthritis in mice. Free Radic Biol Med 2017; 108:487-499. [PMID: 28419865 DOI: 10.1016/j.freeradbiomed.2017.04.016] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 04/13/2017] [Accepted: 04/15/2017] [Indexed: 12/11/2022]
Abstract
Septic arthritis is a severe and rapidly debilitating disease associated with severe joint pain, inflammation and oxidative stress. Nitroxyl (HNO) has become a nitrogen oxide of significant interest due to its pharmacological endpoints that are potentially favorable for treating varied diseases. However, whether HNO also serves as a treatment to septic arthritis is currently unknown. The aim of this study was to investigate the effect of the HNO donor, Angeli's salt (AS), in the outcome of chronic Staphylococcus aureus (S. aureus)-induced septic arthritis in mice. Daily treatment with AS inhibited mechanical hyperalgesia and inflammation (edema, leukocyte migration, cytokines release and NF-κB activation, and oxidative stress) resulting in reduced disease severity (clinical course, histopathological changes, proteoglycan levels in the joints, and osteoclastogenesis). In addition, AS decreased the number of S. aureus colony forming unities in synovial tissue, enhanced the bactericidal effect of macrophages and inhibited the worsening of systemic inflammatory response (leukocyte counts in the lung and systemic proinflammatory cytokine concentration). Our results suggest for the first time the therapeutic potential of AS in a model of septic arthritis by mechanisms involving microbicidal effects, anti-inflammatory actions and reduction of disease severity.
Collapse
Affiliation(s)
- Larissa Staurengo-Ferrari
- Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil
| | - Kenji W Ruiz-Miyazawa
- Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil
| | - Felipe A Pinho-Ribeiro
- Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil
| | - Talita P Domiciano
- Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil
| | - Victor Fattori
- Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil
| | - Sandra S Mizokami
- Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil
| | - Jacinta S Pelayo
- Departamento de Microbiologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil
| | - Juliano Bordignon
- Laboratorio de Virologia Molecular, Instituto Carlos Chagas, FIOCRUZ, CEP 81350-010 Curitiba, Paraná, Brazil
| | - Florêncio Figueiredo
- Laboratory of Pathology, Faculty of Medicine, University of Brasilia, CEP 70910-900 Brasilia, Brazil
| | - Rubia Casagrande
- Department of Pharmaceutical Sciences, Healthy Sciences Centre, Londrina State University, Av. Robert Koch, 60, CEP 86038-350 Londrina, Paraná, Brazil
| | - Katrina M Miranda
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA
| | - Waldiceu A Verri
- Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, Cx Postal 10011, CEP 86057-970 Londrina, Paraná, Brazil.
| |
Collapse
|
25
|
Stafford CA, Nachbur U. A NODding acquaintance with ER stress. Cell Death Discov 2016; 2:16037. [PMID: 27551527 PMCID: PMC4979412 DOI: 10.1038/cddiscovery.2016.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- C A Stafford
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3010, Australia
| | - U Nachbur
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3010, Australia
| |
Collapse
|
26
|
Xu J, Jiang C, Zhu W, Wang B, Yan J, Min Z, Geng M, Han Y, Ning Q, Zhang F, Sun J, Meng L, Lu S. NOD2 pathway via RIPK2 and TBK1 is involved in the aberrant catabolism induced by T-2 toxin in chondrocytes. Osteoarthritis Cartilage 2015; 23:1575-85. [PMID: 25917637 DOI: 10.1016/j.joca.2015.04.016] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 03/27/2015] [Accepted: 04/15/2015] [Indexed: 02/02/2023]
Abstract
OBJECTIVE This study aimed to identify the key intracellular pattern recognition receptor (PRR) and its role in the unbalanced extracellular matrix gene expressions of chondrocytes treated by T-2 toxin, a potential etiological factor for cartilage damages. DESIGN Differential expressions of intracellular PRRs after T-2 toxin treatment were screened by RT-qPCR in chondrocytes. RNAi was used to knockdown the expression of NOD2 and its two downstream signal molecules, RIPK2, and TBK1, for observing the effects of NOD2 pathway on regulation of metabolism gene expressions by RT-qPCR. The matrix metalloproteinases (MMP) activity was determined by gelatin zymography. The inhibitor of NF-κB and ROS scavenger were exploited to analyze the mechanism of NOD2 up-regulation in chondrocytes treated with T-2 toxin. RESULTS In chondrocytes treated with T-2 toxin, anabolism genes were down-regulated whereas catabolism genes were up-regulated, and NOD2 was identified as a significantly up-regulated gene. Intervening NOD2 expression via RNAi could ameliorate the down-regulation of anabolism genes, while inhibit the up-regulation of catablolism genes induced by T-2 toxin in chondrocytes. RNAi of RIPK2 and TBK1 in chondrocytes could obtain the similar outcome. Furthermore, up-regulation of NOD2 expression induced by T-2 toxin could be abrogated by pretreating the cells with inhibitors of NF-κB and scavenger of ROS. CONCLUSION T-2 toxin could up-regulate NOD2 expression via ROS/NF-κB pathway and activate NOD2 signaling pathway. The up-regulated NOD2 would affect the metabolism gene expressions and MMP activity in chondrocytes via RIPK2 and TBK1. The findings add new insights into understanding NOD2 effects on chondrocytes treated with T-2 toxin.
Collapse
Affiliation(s)
- J Xu
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - C Jiang
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - W Zhu
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - B Wang
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - J Yan
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - Z Min
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - M Geng
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - Y Han
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - Q Ning
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - F Zhang
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - J Sun
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - L Meng
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China.
| | - S Lu
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, PR China; Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China.
| |
Collapse
|
27
|
Franca RFO, Vieira SM, Talbot J, Peres RS, Pinto LG, Zamboni DS, Louzada-Junior P, Cunha FQ, Cunha TM. Expression and activity ofNOD1andNOD2/RIPK2signalling in mononuclear cells from patients with rheumatoid arthritis. Scand J Rheumatol 2015. [DOI: 10.3109/03009742.2015.1047403] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
28
|
Wang Z, Liu M, Nie X, Zhang Y, Chen Y, Zhu L, Chen X, Chen L, Chen H, Zhang J. NOD1 and NOD2 control the invasiveness of trophoblast cells via the MAPK/p38 signaling pathway in human first-trimester pregnancy. Placenta 2015; 36:652-60. [DOI: 10.1016/j.placenta.2015.03.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 02/15/2015] [Accepted: 03/04/2015] [Indexed: 01/01/2023]
|
29
|
Majewska-Szczepanik M, Strzepa A, Marcińska K, Wen L, Szczepanik M. Epicutaneous immunization with TNP-Ig and Zymosan induces TCRαβ+ CD4+ contrasuppressor cells that reverse skin-induced suppression via IL-17A. Int Arch Allergy Immunol 2014; 164:122-36. [PMID: 24993442 DOI: 10.1159/000363446] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 05/07/2014] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Our previous work showed that epicutaneous (EC) immunization with protein antigen e.g. TNP-conjugated mouse immunoglobulin (TNP-Ig) in the form of a patch prior to hapten sensitization inhibits Th1-mediated contact hypersensitivity (CHS) in mice. We also found that suppression of CHS was mediated by TCRαβ+ CD4+ CD8+ T suppressor cells producing TGF-β. The aim of this study was to investigate the role of innate immunity in the suppression of CHS. METHODS Mice were immunized by applying gauze patches containing protein antigen alone or in the presence of zymosan, and were then tested for the CHS response. Adoptive cell transfer experiments were used to study the mechanisms involved in the reversal of skin-induced suppression. The influence of EC immunization on cytokine production by lymph node cells was measured by ELISA. RESULTS We found that EC immunization with TNP-Ig and zymosan before trinitrophenyl chloride sensitization reverses skin-induced suppression, demonstrated in vivo and in vitro. The reversal of skin-induced suppression was transferable by antigen-specific TCRαβ+ CD4+ T contrasuppressor cells. Furthermore, we showed that the contrasuppression was IL-17A-dependent and TLR2- and MyD88-independent. CONCLUSIONS Our work strongly suggests that EC immunization with protein antigen and zymosan reverses skin-induced suppression and that this approach may be a potential tool to increase the immunogenicity of weakly immunogenic antigens.
Collapse
Affiliation(s)
- Monika Majewska-Szczepanik
- Department of Medical Biology, Faculty of Health Sciences, Jagiellonian University College of Medicine, Krakow, Poland
| | | | | | | | | |
Collapse
|
30
|
Jakopin Ž. Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway. J Med Chem 2014; 57:6897-918. [PMID: 24707857 DOI: 10.1021/jm401841p] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Dysregulation of nucleotide-binding oligomerization domains 1 and 2 (NOD1 and NOD2) has been implicated in the pathology of various inflammatory disorders, rendering them and their downstream signaling proteins potential therapeutic targets. Selective inhibition of NOD1 and NOD2 signaling could be advantageous in treating many acute and chronic diseases; therefore, harnessing the full potential of NOD inhibitors is a key topic in medicinal chemistry. Although they are among the best studied NOD-like receptors (NLRs), the therapeutic potential of pharmacological modulation of NOD1 and NOD2 is largely unexplored. This review is focused on the scientific progress in the field of NOD inhibitors over the past decade, including the recently reported selective inhibitors of NOD1 and NOD2. In addition, the potential approaches to inhibition of NOD signaling as well as the advantages and disadvantages linked with inhibition of NOD signaling are discussed. Finally, the potential directions for drug discovery are also discussed.
Collapse
Affiliation(s)
- Žiga Jakopin
- Faculty of Pharmacy, University of Ljubljana , Aškerčeva 7, SI-1000 Ljubljana, Slovenia
| |
Collapse
|
31
|
Li J, Wu S, Wang MR, Wang TT, Li BK, Zhu JM. Potential roles of nucleotide-binding oligomerization domain 2 in the pathogenesis of systemic lupus erythematosus. Rheumatol Int 2014; 34:1339-44. [PMID: 24599604 DOI: 10.1007/s00296-014-2975-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 02/17/2014] [Indexed: 01/09/2023]
Abstract
Nucleotide-binding oligomerization domain 2 (NOD2) is one of the most prominent member of the NOD-like receptors protein family that functions as intracellular pattern recognition receptors. Numerous studies have suggested the importance of NOD2 in defensing against microbial infections, regulation of the inflammatory process. It is shown that NOD2 contributes to the pathogenesis of various autoimmune and chronic inflammatory diseases, such as Crohn's disease, rheumatoid arthritis. The aim of this study is to summarize our current understandings of NOD2 function and the role of NOD2 in systemic lupus erythematosus (SLE). The following databases were searched: Pubmed, EMBASE and Web of Science for English-language sources, using the terms "lupus," "systemic lupus erythematosus," ''SLE," "immunity," "inflammatory" and "NOD2." Emerging data evidences that NOD2 has important biological effects in autoimmunity and inflammatory and might take part in the pathogenesis of SLE. Studies exploring the relationship between NOD2 and SLE are very limited. Whether NOD2 could be a potentially valuable therapeutic target for treatment for SLE, more understanding of the mechanism of NOD2 is needed in the future in SLE.
Collapse
Affiliation(s)
- Jing Li
- Department of Public Health and General Medicine, School of Integrated Traditional and Western Medicine, Anhui University of Chinese Medicine, Hefei, 230038, Anhui, China
| | | | | | | | | | | |
Collapse
|
32
|
Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 2013; 14:9-23. [PMID: 24336102 DOI: 10.1038/nri3565] [Citation(s) in RCA: 456] [Impact Index Per Article: 41.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Entry of bacteria into host cells is an important virulence mechanism. Through peptidoglycan recognition, the nucleotide-binding oligomerization domain (NOD) proteins NOD1 and NOD2 enable detection of intracellular bacteria and promote their clearance through initiation of a pro-inflammatory transcriptional programme and other host defence pathways, including autophagy. Recent findings have expanded the scope of the cellular compartments monitored by NOD1 and NOD2 and have elucidated the signalling pathways that are triggered downstream of NOD activation. In vivo, NOD1 and NOD2 have complex roles, both during bacterial infection and at homeostasis. The association of alleles that encode constitutively active or constitutively inactive forms of NOD2 with different diseases highlights this complexity and indicates that a balanced level of NOD signalling is crucial for the maintenance of immune homeostasis.
Collapse
Affiliation(s)
- Dana J Philpott
- 1] Department of Immunology, University of Toronto, Toronto M5S 1A8, Canada. [2]
| | - Matthew T Sorbara
- 1] Department of Immunology, University of Toronto, Toronto M5S 1A8, Canada. [2]
| | | | - Kenneth Croitoru
- Institute of Medical Science, Department of Medicine, University of Toronto, Toronto M5S 1A8, Canada
| | - Stephen E Girardin
- 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada. [2]
| |
Collapse
|
33
|
Zhong Y, Kinio A, Saleh M. Functions of NOD-Like Receptors in Human Diseases. Front Immunol 2013; 4:333. [PMID: 24137163 PMCID: PMC3797414 DOI: 10.3389/fimmu.2013.00333] [Citation(s) in RCA: 210] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2013] [Accepted: 10/02/2013] [Indexed: 12/26/2022] Open
Abstract
Nucleotide-binding and oligomerization domain NOD-like receptors (NLRs) are highly conserved cytosolic pattern recognition receptors that perform critical functions in surveying the intracellular environment for the presence of infection, noxious substances, and metabolic perturbations. Sensing of these danger signals by NLRs leads to their oligomerization into large macromolecular scaffolds and the rapid deployment of effector signaling cascades to restore homeostasis. While some NLRs operate by recruiting and activating inflammatory caspases into inflammasomes, others trigger inflammation via alternative routes including the nuclear factor-κB, mitogen-activated protein kinase, and regulatory factor pathways. The critical role of NLRs in development and physiology is demonstrated by their clear implications in human diseases. Mutations in the genes encoding NLRP3 or NLRP12 lead to hereditary periodic fever syndromes, while mutations in CARD15 that encodes NOD2 are linked to Crohn’s disease or Blau’s syndrome. Genome-wide association studies (GWASs) have identified a number of risk alleles encompassing NLR genes in a host of diseases including allergic rhinitis, multiple sclerosis, inflammatory bowel disease, asthma, multi-bacillary leprosy, vitiligo, early-onset menopause, and bone density loss in elderly women. Animal models have allowed the characterization of underlying effector mechanisms in a number of cases. In this review, we highlight the functions of NLRs in health and disease and discuss how the characterization of their molecular mechanisms provides new insights into therapeutic strategies for the management of inflammatory pathologies.
Collapse
Affiliation(s)
- Yifei Zhong
- Department of Microbiology and Immunology, McGill University , Montreal, QC , Canada
| | | | | |
Collapse
|
34
|
Jun JC, Cominelli F, Abbott DW. RIP2 activity in inflammatory disease and implications for novel therapeutics. J Leukoc Biol 2013; 94:927-32. [PMID: 23794710 DOI: 10.1189/jlb.0213109] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
The role of NOD2 and RIP2 in inflammatory disease has been paradoxical. Whereas loss-of-function NOD2 polymorphisms cause CD, a granulomatous disease of the gastrointestinal tract, gain-of-function mutations cause EOS-a granulomatous disease primarily affecting the skin, joints, and eyes. Thus, gain-of-function mutations and loss-of-function polymorphisms cause granulomatous inflammatory disease, only in different anatomic locations. The situation is complicated further by the fact that WT NOD2 and WT RIP2 activity has been implicated in diseases such as asthma, inflammatory arthritis and MS. This article reviews the role that the NOD2:RIP2 complex plays in inflammatory disease, with an emphasis on the inhibition of this signaling pathway as a novel pharmaceutical target in inflammatory disease.
Collapse
Affiliation(s)
- Janice C Jun
- 1.Case Western Reserve University School of Medicine, Wolstein Research Bldg., 2103 Cornell Rd., Room 6532, Cleveland, OH 44122, USA.
| | | | | |
Collapse
|
35
|
Campbell L, Williams H, Crompton RA, Cruickshank SM, Hardman MJ. Nod2 deficiency impairs inflammatory and epithelial aspects of the cutaneous wound-healing response. J Pathol 2013; 229:121-31. [PMID: 22951952 DOI: 10.1002/path.4095] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2012] [Revised: 08/01/2012] [Accepted: 08/17/2012] [Indexed: 02/06/2023]
Abstract
Infection is a significant causative factor in human chronic wounds that fail to heal. Complex innate host response mechanisms have evolved whereby potentially harmful pathogens are recognized by multiple host pattern recognition receptors (PRRs), yet understanding of PRR function, or dysfunction, in the context of chronic wounds remains limited. NOD2, a cytoplasmic PRR, has been strongly implicated in chronic inflammation of the gut, where loss-of-function mutations have been linked to Crohn's disease; however, cutaneous Nod2 function remains poorly characterized. Here we demonstrate an important role for Nod2 in murine skin wound healing. Cutaneous Nod2 is induced in key wound cell types in response to injury. In the absence of Nod2, mice display a substantial delay in acute wound repair associated with epithelial and inflammatory changes. Specifically, Nod2-null mice display altered epidermal migration and proliferation, an initial delay in neutrophil recruitment associated with decreased expression of the chemokine receptor CXCR2, and reduced numbers of alternatively activated macrophages (Ym1(+) cells). Somewhat surprisingly, these Nod2-null phenotypes were associated with little or no expression change in other PRRs, even though compensatory mechanisms have been shown to exist. In this study we show that healing in TLR2-null mice was essentially normal. These findings reveal a novel intrinsic role for Nod2 in cutaneous wound repair in addition to its role in recognizing invading pathogens.
Collapse
|
36
|
Moreira LO, Zamboni DS. NOD1 and NOD2 Signaling in Infection and Inflammation. Front Immunol 2012; 3:328. [PMID: 23162548 PMCID: PMC3492658 DOI: 10.3389/fimmu.2012.00328] [Citation(s) in RCA: 190] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Accepted: 10/17/2012] [Indexed: 12/12/2022] Open
Abstract
Sensing intracellular pathogens is a process mediated by innate immune cells that is crucial for the induction of inflammatory processes and effective adaptive immune responses against pathogenic microbes. NOD-like receptors (NLRs) comprise a family of intracellular pattern recognition receptors that are important for the recognition of damage and microbial-associated molecular patterns. NOD1 and NOD2 are specialized NLRs that participate in the recognition of a subset of pathogenic microorganisms that are able to invade and multiply intracellularly. Once activated, these molecules trigger intracellular signaling pathways that lead to the activation of transcriptional responses culminating in the expression of a subset of inflammatory genes. In this review, we will focus on the role of NOD1 and NOD2 in the recognition and response to intracellular pathogens, including Gram-positive and Gram-negative bacteria, and on their ability to signal in response to non-peptidoglycan-containing pathogens, such as viruses and protozoan parasites.
Collapse
Affiliation(s)
- Lilian O Moreira
- Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio de Janeiro Rio de Janeiro, Brazil
| | | |
Collapse
|